“In the whole global accounting of Crispr [gene editing] therapies, somatic cell genome editing is going to be a large fraction of that,” says Krishanu Saha, a bioengineer at University of Wisconsin-Madison who is currently part of a consortium investigating the technique’s safety. “I mean, that’s certainly the case now, if you look at where trials are, where investment is.”
University Communications